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Background: Ligand molecules conjugated to polylysine 
can be electrostatically bound to DNA and can bind 
receptors or antigens on the surface of cells, delivering the 
DNA into specific cells and tissues. Several researchers 
have used this approach to generate non-viral vehicles for 
the efficient delivery of DNA to specific cells. We have 
attempted to adopt this general approach to the cell- 
specific delivery of magnetic contrast agents for use in 
magnetic resonance imaging (MRI). 
Results: We have synthesized a new class of agents capable 
of both transfecting genes into cells and enhancing the 
contrast of the targeted cells for MRI. DNA is used both 
to encode a marker gene and as a molecular scaffold, which 
electrostatically binds polylysine conjugated to transferrin, 
an iron uptake protein, and polylysine modified with 
gadolinium chelated to diethylenetriaminepetaacetic acid. 
When cells displaying the transferrin receptor are treated 
with these particles, high levels of gene expression are 
observed, higher than with control particles composed 
only of transferrin, polylysine and DNA. The treated cells 
show specific MRI contrast enhancement, which did not 
require expression of the marker gene. 
Conclusions: The development of this class of particles 
permits the use of novel protocols by which genes for 
genetic therapy and agents for MRI contrast are co- 
transported. These protocols may allow non-invasive 
MRI monitoring of DNA delivery for gene therapy in 
real time. 
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Introduction 
Magnetic resonance imaging (MRI) has become a pow- 
erful tool in clinical and research settings because it is 
non-invasive and yields an accurate volume rendering of 
a specimen. Using magnetic field gradients and selective 
radio frequency (RF) pulses, a one-, two- or three- 
dimensional image of the specimen is obtained. Typically, 
the image is based upon the NMR signal from the 
protons of water where the signal intensity in a given 
volume element (voxel) is a function of the water con- 
centration and the relaxation times of the spins within 
the voxel (T1 and T.J. Local variations in these three 
parameters provide the vivid contrast observed in MRI 
images [l]. The relaxation times can be strongly affected 
by MRI contrast agents, permitting specific fluid com- 
partments or cells to be selectively followed. Unlike 
light-microscope imaging techniques that are based on 
the use of organic dyes or fluorochromes, neither MRI 
nor MRI contrast agents produce toxic by-products 
from photo-bleaching. Furthermore, MRI is not limited 
by light scattering or other optical aberrations, permit- 
ting high field strength instruments (>7 Tesla) to gener- 
ate high resolution (lo-15 pm) images of developing 
insects, fish, amphibia and mammals [2]. 
A major limitation on the use of MRI in basic research 
settings has been the invasive manipulations and/or 
microinjections required to label cells or tissues. In clinical 
settings, limitations resulting from similar constraints 
together with the potential for using MRI contrast agents 
to target specific tissues or tumors in viva, have stimulated 
- 
the syntheses of new paramagnetic agents covalently 
attached to biological macromolecules [3]. To significantly 
enhance the observed contrast, however, antibodies or 
other targeting molecules must bind very large numbers 
of paramagnetic complexes [4]. Such high ratios of con- 
trast agent to biomolecule cripple the targeting molecule 
due to ionic and steric effects. Therefore, much of the 
current research in this field has focused on the use of 
liposomes as carriers of high concentrations of contrast 
agents [5], iron oxide particles as high signal strength T, 
contrast agents [6], and more recently, highly modified 
starburst dendrimers of paramagnetic agents [7]. 
Here we report a different strategy, based on methods 
currently under development for the delivery of nucleic 
acids to specific cells, to deliver both exogenous genes 
and large numbers of MRI contrast agents to cells. 
Polypeptides composed exclusively of lysine residues 
bind electrostatically to DNA and cause it to condense 
by neutralizing the negative charge. Ligand molecules 
conjugated to polylysine can thus be bound to DNA. 
Binding of the ligand molecule within the DNA-ligand 
complex to receptors or antigens on the cell surface 
delivers the complex with high efficiency into specific 
cells and tissues [S-15]. In our modification of this 
scheme, paramagnetic contrast agents are covalently 
attached to polylysine for incorporation into a 
DNA-polycation complex (Fig. 1). For our first test case, 
we used ternary particles containing the following com- 
ponents: i) DNA encoding the firefly luciferase reporter 
gene, ii) poly-L-lysine attached to human transferrin, a 
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Fig. 1. Summary of the formation of ternary complexes for receptor-mediated uptake of DNA and MRI contrast agents. DNA is partially 
condensed by the addition of sub-optimal quantities of transferrin-polylysine (Tf-PL). Full condensation to electro-neutrality follows 
the addition of Cd-DTPA-PDL, producing particles with high transfection efficiency and MRI contrast enhancement. 
protein involved in iron uptake, and iii) poly-D-lysine 
(PDL) attached to varying numbers of the paramagnetic 
contrast agent, gadolinium diethylenetriaminepetaacetic 
acid (Gd-DTPA). Uptake of one of these particles by 
cells expressing the transferrin receptor results in delivery 
of -1500 Gd ions per cell, achieving the high ratio of 
contrast agent per biomolecule required for in vim label- 
ing. After incubation of human T-cell leukemia derived 
K562 cells with the ternary complexes, detectable MRI 
contrast enhancement is observed at nearly single-cell 
resolution. Moreover, the level of gene expression 
observed in these cells is higher than the levels observed 
using control particles that do not contain the MRI 
contrast agent. 
Results and discussion 
Synthesis and characterization of Cd-DTPA 
conjugates of PDL 
We prepared a series of DTPA-modified PDL deriva- 
tives with varying numbers of labeled sites. Simply 
dissolving PDL in aqueous solutions at high pH, fol- 
lowed by addition of DTPA anhydride, invariably leads 
to a large distribution of products. At concentrations 
above 100 PM PDL, the major product isolated from 
this reaction is a crosslinked material of high molecular 
weight, as revealed by fast protein liquid chromato- 
graphy (FPLC). By maintaining the PDL concentration 
below 100 p,M and controlling the rate of anhydride 
addition, we have modified the PDL used in these 
experiments with as few as 7 and as many as 60 DTPA 
chelates with no evidence of crosslinking. 
Fluorescence titration experiments were performed to 
assess the degree of substitution on the 180 residue PDL 
backbone resulting from various molar input ratios of 
DTPA and PDL. Europium chelates of DTPA form 
readily at room temperature and show characteristic and 
distinct fluorescence with large Stoke’s shifts and long 
fluorescent lifetimes.Titration of the DTPA-PDL conju- 
gates with EuC& produced increasing fluorescence 
intensities followed by inflections in the curves corre- 
sponding to complete saturation of the DTPA sites [16]. 
The ratios of DTPA to PDL determined by fluorescence 
titration of the various conjugates is shown in Table 1 
along with the calculated number of unmodified (and 
thus positively charged) lysines per DTPA site. 
Previous studies on the interaction between DNA and 
polylysine have suggested that polymers containing seven 
or more lysine monomers readily form neutral particles 
with DNA, whereas shorter polymers do not [17]. 
Therefore, we anticipated that PDL modified with 10 and 
22 Gd chelates per PDL chain (16 lysines and 6.7 lysines 
per Gd chelate, respectively) would interact readily with 
DNA, whereas PDL modified with 42 and 51 Gd 
chelates, which have shorter stretches of unmodified 
lysine residues, would not. 
To rapidly test this hypothesis, the effect of PDL conjugates 
on the secondary structure of DNA in solution was in- 
directly monitored using a IN hyperchromicity assay. 
Polycations such as polylysine that interact electrostatically 
with DNA alter the absorbance and optical rotation char- 
acteristics of the nucleic acid [18]. Titration of DNA with 
unmodified PDL produces a curve with peak UV 
absorbance corresponding to a 1:l ratio of lysine 
monomers to nucleotide residues (Fig. 2).A nearly identical 
curve is produced when transferrin-polylysine is added to 
the DNA.The PDL conjugates with ratios of Gd-DTPA 
per PDL molecule of 10 and 22 show similar effects, sug- 
gesting that these modified PDL molecules interact with 
DNA (Fig. 2). In contrast, PDL conjugates having larger 
numbers of DTPA chelates (42 and 51) produce no 
Table 1. Effect of reagent ratios on modification of pOly-D-IySine 
with DTPA. 
DTPA:poiy-D-lysine Unmodified lysine units 
input ratio Output ratio per DTPA site 
50 IO 16.0 
100 22 6.7 
200 42 3.0 
400 51 2.3 
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0.6 
0.0 
0 2 4 6 8 
Polylysine equivalents (kg) per 6 Fg DNA 
Fig. 2. PDL modified with 10 or 22 Cd chelates per PDL mole- 
cule bind to DNA. A UV hyperchromicity assay was used to 
assess binding of polylysine to DNA. Increasing quantities of 
PDL or modified polylysine were added to 6 pg plasmid DNA 
in 1 .O ml HBS while monitoring absorbance at 260 nm. The 
addition of unmodified PDL (0) or transferrin-polylysine (0) to 
DNA produces characteristic and nearly identical changes in 
UV absorbance. Peak absorbance occurs at approximately a 
1:l molar ratio of lysine monomers to nucleotides, corre- 
sponding to electro-neutrality and optimal transfection effi- 
ciency. Titration of DNA with PDL modified with 10 Cd 
chelates per PDL molecule (Gd-DTPA(,,,-PDL; v) or 22 Gd 
chelates (Gd-DTPA (22)-PDL; v) results in distinct but grossly 
similar curves. In contrast, Gd-DTPA(,, -PDL (0) and 
Cd-DTPA (s,,-PDL (W) have minimal e fects on DNA ? 
absorbance, consistent with a reduced ability of these heavily 
labeled PDL molecules to interact with DNA. 
observable increase in the UV absorbance, suggesting only 
minimal interaction with the DNA (Fig. 2). Based on these 
results, the conjugate containing a ratio of 22 Gd-DTPA 
sites per PDL molecule (Gd-DTPA(,,)-PDL) was used in 
subsequent experiments. 
Luciferase gene delivery by particles containing DNA, 
Tf-PL and Gd-DTPA-PDL 
Particles were formed by adding varying amounts of 
transferrin conjugated to poly-L-lysine (Tf-PL) to 
plasmid DNA encoding the firefly luciferase gene, 
followed by the addition of a sufficient amount of 
Gd-DTPA(,,)-PDL to neutralize the remaining negative 
charge of the DNA.Tf-PL (3 p,g, equivalent to 0.4 pg of 
unmodified polylysine) was added to 6 pg of DNA to 
neutralize approximately one tenth of the DNA charge. 
The remainder of the DNA charge was neutralized by 
the addition of either 4 kg of unconjugated PDL or an 
equivalent amount of Gd-DTPA(,,)-PDL. 
High luciferase expression resulted from incubation of 
the particles containing Gd-DTPA with human ery- 
throleukemic K562 cells in the presence of the lysoso- 
matropic agent, chloroquine (Fig. 3A). It was surprising 
that the level of gene expression was increased approxi- 
mately two-fold over that obtained using particles 
lacking Gd-DTPA-PDL (Fig. 3B). This enhancement of 
gene expression may be due to neutralization of a 
portion of the charges on the polylysine backbone by 
the Gd-DTPA chelates. In the absence of chloroquine, 
gene expression was not observed (Fig. 3D). 
Our data indicate that gene delivery takes place through 
the transferrin receptor via receptor-mediated endo- 
cytosis. Neither unmodified polylysine [S] nor 
Gd-DTPA-PDL (data not shown) on their own facili- 
tate the transfer of DNA into K562 cells. Furthermore, 
gene expression is blocked by adding iron-loaded trans- 
ferrin to the medium during transfection (Fig. 3C) but 
not by adding apotransferrin, which does not bind to the 
receptor at neutral pH [19]. 
Complexes containing DNA, Tf-PL and Gd-DTPA-PDL 
enhance the MRI contrast of cells 
Having demonstrated that DNA complexes containing 
Tf-PL and Gd-DTPA-PDL are effective gene-delivery 
vehicles, we then examined the ability of these particles 
to enhance MRI contrast of transfected K562 cells in 
vitro. Cells treated with these particles were washed 
extensively in hepes-buffered saline (HBS) and gently 
loaded into sealed glass capillary tubes, and T1-weighted 
images (T,/T, = 200 ms/13 ms) were acquired (Fig. 4). 
MRI contrast enhancement is clearly observed in cells 
exposed to the Gd-containing particles (Fig. 4a). In con- 
trast, cells exposed to particles lacking Gd-DTPA-PDL 
show no such enhancement (Fig. 4b). Enhancement of 
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Fig. 3. Transfection of cells is specific and is enhanced using par- 
ticles containing Cd-modified PDL. Ternary complexes were 
formed with 6 pg DNA, 3 kg Tf-PL and 4 pg (unmodified lysine 
equivalents) of either Gd-DTPA 
K2)- 
PDL (column A) or PDL 
(column B). Each bar represents t e average of values obtained 
in five independent transfection experiments using K562 
cells and normalized to IO6 cells per experiment. Using 
Gd-DTPA(22)-PDL-containing particles, gene expression was 
measured in the presence of 20 pg of iron-loaded transferrin to 
show the effect of competitive uptake (column C) and in the 
absence of chloroquine to assess the mechanism of cytoplasmic 
delivery (column D). In these experiments, 1 ng of luciferase 
produces -lo5 light units. 
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Fig. 4. The ternary complex containing Cd-DTPA-PDL delivers 
the MRI contrast agent to K562 cells via the transferrin receptor. A 
two-dimensional horizontal MRI slice is shown through three 
capillary tubes (2 mm inner diameter) loaded with labeled or 
control K562 cells. (a) Cells exposed to the ternary complex con- 
taining 6 pg DNA, 3 t.r,g Tf-PL and 4 pg Cd-DTPA(,,)--PDL. Bright 
spots represent aggregates of contrast-agent-containing cells. 
Mean intensity: 232 + 25. (b) Cells treated with control com- 
plexes containing 4 pg unmodified PDL in lieu of the gadolinium- 
modified PDL. Mean intensity: 121 f 30. (c) Cells treated as in (a) 
with the addition of 20 t.r,g iron-loaded transferrin to competitively 
block uptake of the ternary complex. Mean intensity: 126 + 30. A 
IO pg ml-’ standard solution of Gd-DTPA in water produces a 
mean intensity of 142 f 32, although it should be noted that MRI 
is extremely sensitive to specific experimental conditions, includ- 
ing solvent composition and viscosity. 
the MRI contrast of cells is competitively inhibited by 
the addition of iron-loaded transferrin, indicating that 
the observed effect is receptor-specific (Fig. 4~). The 
magnetic resonance imaging results obtained in these 
experiments were the same in the presence or absence of 
chloroquine, suggesting that escape from the lysosome is 
not necessary for MRI enhancement. 
In summary, we have shown that modified polycations 
can be used to deliver DNA and other molecules to 
cells at high efficiency. Previous work has shown that 
-20 transferrin molecules per complex are necessary to 
impart receptor-specific uptake of DNA [8]. This 
number of target molecules can be achieved with as 
little as lo-15 % of the polylysine necessary to con- 
dense a 6 kb plasmid.The remaining 90 % of the DNA 
negative charge can be neutralized by the addition of 
approximately 4 pg of unmodified polylysine, or an 
equivalent amount of modified polylysine. Previous 
work has demonstrated the utility of modifying this 
neutralizing polylysine with agents that disrupt endo- 
somes, thus enhancing the escape of the DNA from 
lysosomal degradation [13-l 51. The coupling of aden- 
ovirus and influenza virus fusogenic peptides has been 
especially fruitful in this regard, resulting in high levels 
of gene expression. In our experiments, the addition of 
chloroquine during transfection served the purpose of 
preventing acidification of the endosome and reducing 
the destruction of the DNA following endocytosis. 
Thus, most of the polylysine used to neutralize the 
DNA could be substituted with chelated Gd3+. 
Inclusion in the complex of another polylysine compo- 
nent that is conjugated to a fusogenic peptide may give 
high levels of gene expression even in the absence 
of chloroquine. 
Using the Gd-DTPA-PDL which we have synthesized, 
22 Gd3+ ions are chelated to each PDL molecule, corre- 
sponding to -1200 Gd3+ ions per plasmid molecule in 
the ternary complex.This greatly exceeds the number of 
contrast agents that can be attached directly to a mono- 
clonal antibody. Moreover, the fast rate of transferrin 
receptor turnover (2 x lo4 transferrin molecules internal- 
ized per minute) results in the uptake of extremely large 
numbers of contrast agent molecules in this system [2O]. 
This uptake is enhanced in vitro when the particles are at 
relatively high concentrations and, prior to transfection, 
cells are starved for iron, inducing an increase in the 
number of transferrin receptors on the cell surface [8]. 
Significance 
The delivery of genes to specific cells and tissues 
for therapeutic and research purposes is of increas- 
ing importance. A new method to track the deliv- 
ery of vectors for gene transfection and genetic 
therapy is imagined based on the work described 
in this report. This method combines a magnetic 
resonance imaging (MRI) contrast agent and a 
receptor-targeted gene delivery vehicle. 
MRI is an ideal tool for non-invasive monitoring 
of human and experimental subjects. We have syn- 
thesized a new class of MRI contrast agents 
capable of transfecting genes into cells and 
enhancing the MRI contrast of these targeted cells 
in vitro. The particles are composed of DNA, 
polylysine attached to transferrin, and polylysine 
modified with a paramagnetic contrast agent. 
Modification of this strategy should produce par- 
ticles capable of functioning in viuo. Such particles 
could be composed of i) DNA encoding a 
reporter or therapeutic gene, ii) polylysine modi- 
fied with transferrin or with an alternative 
cell-targeting molecule, such as a monoclonal 
antibody, iii) polylysine modified with fusogenic 
peptides to facilitate release from the endosomal 
pathway and iv) polylysine (D or L forms) modi- 
fied with Gd chelates. Co-transport of DNA and 
MRI contrast agents of this type should result in 
high levels of gene expression. These particles may 
prove extremely useful in targeting specific cells 
in viva as they offer a means other than marker 
gene expression to monitor construct uptake. 
With such a tool, clinicians and experimentalists 
may be able to non-invasively monitor delivery of 
genetic therapeutic agents in real time. 
Materials and methods 
Preparation of Tf-PL 
Human transferrin (Tf, Sigma) was conjugated to poly-L-lysine 
(PL) with an average chain length of 220 residues (Sigma) via 
sialic acid residues on transferrin as described [21], or the 
Tf-PL conjugate was purchased directly from Sigma. Modified 
polylysine (Tf-PL) with average molar ratios of transferrin to 
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polylysine of 2.2-2.5 was dissolved in HBS (20 mm Hepes, 
150 mM NaCl, pH 7.4) at a working concentration of 100 pg 
ml-’ for use in subsequent experiments. 
Preparation of DTPA-PDL 
PDL of average chain length 180 was purified by FPLC size- 
exclusion chromatography employing a 10 x 30 Pharmacia 
Superdex 75 column using 0.15 M NaCl, 0.15 M NaPi, 
pH 7.0 buffer.The purified PDL was desalted by gel filtration 
using Sephadex G-25 and dried in vacua. The dry PDL was 
weighed and the total number of lysine monomer units veri- 
fied spectrophotometrically via a ninhydrin assay [22]. PDL 
(0.01 M) was placed in a round-bottomed flask and dissolved 
in 0.05 M HEPES, pH 9.5. Freshly prepared DTPA anhydride 
was added slowly with stirring. The pH of the solution was 
monitored and maintained at 9.5 throughout the course of the 
reaction using a 3 % NaOH solution. The molar ratios of 
DTPA-anhydride to PDL used in these experiments was 50:1, 
lOO:l, 2OO:l and 4OO:l. The reaction was allowed to proceed 
at room temperature for 1 h after complete addition of the 
anhydride, and the crude material was purified by FPLC. 
Determination of DTPA content by fluorescence titration 
The binding of lanthanide metals such as gadolinium, europium 
and terbium to chelating agents produces fluorescence with 
large Stoke’s shifts and fluorescence lifetimes. Eu3+ (unlike Gd3’) 
rapidly coordinates with DTPA derivatives, producing a strong 
fluorescent signal that was monitored to assay DTPA content of 
the various DTPA-PDL conjugates. Samples of the purified 
DTPL~-PDL were diluted in 0.05 M HEPES, pH 7.4 to a final 
concentration of 2-4 x lop5 M. Small volumes (<20 p,l) of 
varying molarities of EuC13 were added to the l-ml samples to 
titrate the free DTPA ligand with minimal dilution of the 
sample. After incubation for 2 min at room temperature, each 
sample was transferred to a Hitachi Model 2400 spectrofluori- 
meter. Measurements were made using excitation at 394 nm and 
monitoring emission at 593 and 616 nm. Molar ratios of DTPA 
per PDL were calculated using the fluorescence titration data 
and the polylysine quantification that was based on ninhydrin as 
an assay for unmodified lysine side-chains [22]. 
Preparation of Cd-DTPA-PDL 
Based on the chelator content determined by Eu titration, a 
1.1 molar excess of GdCl, was added to 1 mg ml-l aliquots of 
the DTPA-PDL in 0.05 M citrate buffer, pH 6.0. The chela- 
tion proceeded for 5 h at 70 “C, and was followed by desalting 
chromatography with Sephadex G25 to remove unbound Gd. 
Gd-DTPA-PDL samples were dissolved in HBS at a working 
concentration of 100 p,g in-l. 
Preparation of MRl/gene delivery particles 
A 6 kilobase-pair plasmid containing the Photinus pyvalis 
luciferase gene under control of the SV40 T-antigen enhancer 
was purchased from Promega (GeneLight control plasmid). 
This plasmid was grown in Erchevickia coli, and DNA was pre- 
pared in 100 kg quantities using a commercially available pro- 
cedure (Qiagen, Midi-100). The supercoiled DNA plasmids 
were dissolved at a concentration of 100 p,g ml-l in 10 mM 
Tris, 1 mM ethylenediaminetetraacetic acid, pH 7.4 (TE). 
Plasmid DNA (6 p,g) in 430 ~1 of HBS was mixed with 3 p+g 
of Tf-PL in 30 ~1 HBS. After 5 min at room temperature, 
various amounts (generally 4 Fg equivalents of polylysine) of 
Gd-DTPA-PDL with differing degrees of Gd substitution 
were added to the sample which was brought to 500 ~1 with 
HBS and allowed to incubate at room temperature for 30 min. 
Transfections 
K562 human leukemia cells (ATCC) were grown in suspension 
in RPM1 1640 medium (Gibco) containing 10 % fetal calf 
serum (Hyclone) containing 100 U ml-’ penicillin, 100 pg ml-’ 
streptomycin and 2 mM glutamine, to a maximum density of 5 
x lo5 cells ml-l. Eighteen to twenty-four hours prior to trans- 
fections, cells were placed in fresh medium containing 50 p,M 
deferroxamine (Sigma) to increase surface presentation of trans- 
ferrin receptors as described [12]. Approximately ten minutes 
prior to transfection, the cells were washed with fresh medium 
containing deferroxamine and placed in a 12-well dish at 
250 000 cells per ml, 2 ml per well. Chloroquine (10 mM) in 
H,O was added to a final concentration of 100 pm. 
The ternary particle in HBS was added slowly to the K562 
cells, which were incubated at 37 “C for 18-24 h. In some 
cases, iron-loaded transferrin (Sigma) was added with the 
ternary complex to competitively inhibit specific uptake of 
the particles. The cells were then washed twice with fresh 
medium without chloroquine or deferroxamine and re- 
suspended at 250 000 cells ml-’ in fresh medium. After 18 h, 
the cells were washed twice in HBS and either gently loaded 
into a glass capillary tube for MR imaging or assayed for 
luciferase expression. Gene expression was monitored by 
lysing cells in 100 ~1 detergent lysis buffer (Clontech). Cell 
lysate (20 ~1) was assayed in a 1 ml standard cell using a 
luminometer and luciferin substrate from Analytical 
Luminescence Laboratory. These results were normalized per 
lo6 cells and confirmed by parallel measurements using a 
scintillation counter (Beckman Instruments). 
MRI image acquisition 
MRI images were acquired using an 11.7 Tesla Bruker AMX 
500 MHz NMR spectrometer with microimaging accessory. 
Glass capillary tubes (2 mm inner diameter) containing -lo6 
cells per tube were immobilized in a plexiglass rack and loaded 
into the MRI bore. Images were acquired using a multi-slice 
3D spin echo protocol where T, = 200 ms,TE = 13 ms and 
the pulse width was set at 9.6 p,s.This protocol results in aT1- 
weighted image and a 512 by 512 by 32 data array. 
Acknowledgements: The authors thank the Baxter Foundation 
for generous support of this work. We thank Pratik Gosh and 
Rex Moats for assistance with image acquisition and Kim 
Mislick for helpful discussions. R.M.K. was supported in part 
by a Summer Undergraduate Research Fellowship at Caltech. 
References 
1. 
2. 
3. 
4. 
5. 
6. 
7. 
a. 
Tootell, R.B.H., et. al., & Belliveau, J.W. (1995). Functional analysis of 
human MT and related visual cortical areas using magnetic resonance 
imaging.]. Neurosci. 15, 321553230. 
Jacobs, R.E. & Fraser, S.E. (1994). Magnetic-resonance microscopy 
of embryonic-cell lineages and movements. Science 263, 681-684. 
Alexander, V. (1995). Design and synthesis of macrocyclic ligands 
and their complexes of lanthanides and actinides. Cbem. Rev. 95, 
273-342. 
Lauffer, R.B. (1991). Targeted relaxation enhancement agents for 
MRI. Map. Reson. Med. 22, 339-342. 
Bogdanov, A.A., Jr, Martin, C., Weissleder, R. & Brady, T.J. (1994). 
Trapping of dextran-coated colloids in liposomes by transient 
binding to aminophospholipid preparation of ferrosomes. Biochim. 
Biophys. Acta 1193, 212-218. 
Shen,?., Weissleder, R., Papisov, M., Bogdanov, A.A., Jr & Brady, T.J. 
(1993). Monocrystalline iron-oxide nanocomnounds (mien) 
physicochemical properties. Map. Reson. Med. 29: 599-604. 
Wiener, E.C., et. a/., & Lauterbur, P.C. (1994). Dendrimer-based 
metal chelates. A new class of magnetic-resonance-imaging contrast 
agents. Map. Reson. Med. 31, 1-8. 
Cotten, M., Wagner, E. & Birnstiel, M.L. (1993). Receptor-mediated 
620 Chemistry & Biology 1995, Vol 2 No 9 
transport of DNA into eukaryotic cells. Methods Fnzymol. 217, 
618-644. 
9. Perales, J.C., Ferkol, T., Beegen, H., Ratnoff, O.D. & Hanson, R.W. 
(1994). Gene transfer in viva: sustained expression and regulation of 
genes introduced into the liver by receptor-targeted uptake. Proc. 
Nat/. Acad. SC;. USA 91, 4086-4090. 
10. Chowdhury, N.R., Wu, C.H., Wu., G.Y., Yerneni, P.C., Bommineni, 
V.R. & Chowdhury, J.R. (1993). Fate of DNA targeted to the liver by 
asialoglycoprotein receptor-mediated endocytosis in viva. Prolonged 
persistence in cytoplasmic vesicles after partial hepatectomy. /. Biol. 
Chem. 268, 11265-I 1271. 
11. Cristiano, R.J., Smith, L.C. & Woo, S.L.C. (1993). Hepatic gene 
therapy. Adenovirus enhancement of receptor-mediated gene deli- 
very and expression in primary hepatocytes. froc. Nat/. Acad. Sci. 
USA 90,2122-2126. 
12. Wagner, E., Cotten, M., Foisner, R. & Birnstiel, M.L. (1991). 
Transferrin polycation DNA complexes-the effect of polycations 
on the structure of the complex and DNA delivery to cells. Proc. 
Nat/. Acad. Sci. USA 88,4255-4259. 
13. Michael, S.I., Huang, C.H., Romer, M.U., Wagner, E., Hu, P.C. & 
Curiel, D.T. (1993). Binding-incompetent adenovirus facilitates mol- 
ecular conjugate-mediated gene-transfer by the receptor-mediated 
endocytosis pathway. /. Viol. Cbem. 268, 6866-6869. 
14. Plank, C., Oberhauser, B., Mechtler, K., Koch, C. & Wagner, E. 
(1994). The influence of endosome-disruptive peptides on gene 
transfer using synthetic virus-like gene-transfer systems. /. Biol. 
Gem. 269, 12918-12924. 
15. Plank, C., Zatloukal, K., Cotten, M., Mechtler, K. & Wagner, E. 
(1992). Gene transfer into hepatocytes using asialoglycoprotein 
receptor mediated endocytosis of DNA complexed with an artificial 
tetra-antennary galactose ligand. Bioconjugafe Chem. 3, 533-539. 
16. Brandt, K.D., Schnobrich, K.E. & Johnson, D.K. (1991). 
Characterization of antibody-chelator conjugates: determination of 
chelator content by terbium fluorescence titration. Bioconjugate 
Chem. 2, 67-70. 
17. Shapiro, J.T., Leng, M. & Felsenfeld, G. (1969). Deoxyribonucleic 
acid-polylysine complexes. Structure and nucleotide specificity. 
Biochemistry 8, 3219-3232. 
18. Minagawa, K., Matsuzawa, Y., Matsumoto, M. & Doi, M. (1991). 
Direct observation of the biphasic conformational change of DNA 
induced by cationic polymers. FEES Lett. 295, 67-69. 
19. Zenke, M., Steinlein, P., Wagner, E. Cotten, M., Beug, H. & 
Birnstiel, M.L. (1990). Receptor-mediated endocytosis of transferrin 
polycation conjugates: an efficient way to introduce DNA into 
hematopoietic cells, Proc. Nat/. Acad. Sci. USA 87, 3655-3659. 
20. Huebers, H.A. & Finch, CA. (1987). The physiology of transferrin 
and transferrin receptors. Physiol. Rev. 67, 520-582. 
21. Wagner, E., Cotten, M., Mechtler, K., Kirlappos, H. & Birnstiel, M.L. 
(1991). DNA-binding transferrin conjugates as functional gene- 
delivery agents. Synthesis by linkage of polylysine or ethidium 
homodimer to the transferrin carbohydrate moiety. Bioconjugate 
Chem. 2,226-231. 
22. Sarin, V.K., Kent, S.B.H., Tam, J.P. & Merrifeld, R.B. (1981). 
Quantative monitoring of solid-phase synthesis by the ninhydrin 
reaction. Anal. b’iochem. 117, 147-157. 
Received: 4 Aug 1995; revisions requested: 22 Aug 1995; 
revisions received: 1 Sep 1995. Accepted: 5 Sep 1995. 
